For a decade, the idea of "returning cells in time" was considered science fiction. In 2026 he crosses the line into real medicine. Life Biosciences of Boston, founded by Harvard researcher David Sinclair, this year opens the first ever clinical trial in humans of "partial reprogramming", a method that aims to reverse cellular aging on demand.
What is going to happen in the experiment?
The experiment will include two groups of patients:
- Up to 12 people with glaucoma of a specific type
- Up to 6 people with NAION, acute damage to the anterior optic nerve that usually ends in blindness
Patients will receive an injection of gene therapy in one eye only. Three of the four original Yamanaka factors will be introduced into the cells, without c-Myc which has been identified as the most dangerous factor of oncogenesis. The genes will only be activated when the patient takes a specific antibiotic. Follow-up period: at least five years.
What are the Yamanaka factors anyway?
In 2006, the Japanese researcher Shinya Yamanaka discovered four genes that, when inserted into an adult cell, return it to a "stem cell" state, a young cell with the potential to become any type of tissue. For the discovery Yamanaka received the Nobel Prize for Medicine in 2012.
The problem: when the four factors are fully activated, the cell loses its identity completely and becomes a stem cell with a high risk of tumor growth. The breakthrough of "partial reprogramming" was the discovery that if the factors are activated in short pulses, the cell becomes younger but maintains its tissue function.
The experiments that led here
Researcher Juan Carlos Izpisoa Belmonte already proved in 2016 that cyclic activation of Yamanka factors extended the life of mice with progeria (accelerated aging syndrome) and improved muscle and heart regeneration in normal old mice. Following this, additional studies reported improved heart regeneration, skin renewal, and improved memory in old mice.
Another researcher, Noah Davidson and his colleagues at Rejuvenate Bio, injected old mice with three Yamanka factors and the mice showed an improvement in all health indicators and a longer life, without the formation of tumors. "We threw the mice in, and honestly, we waited for them to die," Davidson said. "But they flourished".
Why in the eyes?
The eye was chosen as the first target in humans for two reasons:
- Biologically isolated. Any risk of tumor formation remains local and does not spread to the body
- Measurement. It is easy to assess success (vision tests) and track cellular changes
In addition, diseases like NAION are in desperate need of treatment: today there is no treatment that restores vision after such an acute injury.
Not only Life Biosciences
They are not alone in the race:
- Altos Labs, raised $3 billion from investors including Jeff Bezos
- Retro Biosciences, Sam Altman's anti-aging company (OpenAI)
- NewLimit, a company of Brian Armstrong (Coinbase)
- Shift Bioscience, based in Cambridge, UK
The risks and what is already known
"Studies in monkeys found no evidence of cancer or any other harmful effects from the procedure," concludes Sharon Rosenzweig-Lipson, Sinclair's colleague at Life Biosciences.
But not all researchers are equally optimistic. "When cells lose their identity, we know that comes with certain kinds of danger," warns Tamir Chandra of the Mayo Clinic.
What does this say about you?
In 2026 treatment is still years away from you. This trial is only the first step: individual patients, specific diseases, 5-year follow-up. Even if it succeeds, it will likely take another 3-5 years before similar treatments gain FDA approval.
But the historical significance is enormous. First time in the 21st century that science can reverse the cellular clock, not just slow it down.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.